ReviewFrontiers in surgery2016
Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.
Review in Frontiers in surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Pooled it
- Midkine as a novel prognostic and therapeutic target in meningioma: insights from single-cell analysis and organoid-based drug validation.Journal of translational medicine · 2026Article
- Review
- Isolated parenchymal cysts associated with a secretory meningioma: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- A Case of Physiologic Enhancement of Scarpa's Ganglia Mimicking Bilateral Vestibular Schwannomas in a Patient With Atypical Meningioma With NF2 Mutation.Case reports in radiology · 2026Article
- Integrated proteomic and targeted Next Generation Sequencing reveal relevant heterogeneity in lower-grade meningioma and ANXA3 as a new target in NF2 mutated meningiomas.EBioMedicine · 2025Article
- Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in bothWorld journal of experimental medicine · 2025Article
- Molecular biomarkers in meningioma (Review).Biomedical reports · 2025Review
- Toxicities Associated with Adjuvant Radiation Therapy in Atypical Meningioma.Advances in radiation oncology · 2025Article
- Seq-ing answers: exploring meningioma biology utilizing bulk RNA-seq-based reference landscapes.Frontiers in oncology · 2025Review
- Middle third falcine meningiomas-surgical nuances for cortical venous preservation.Acta neurochirurgica · 2024Article
- Article
- A machine learning-based integrated clinical model for predicting prognosis in atypical meningioma patients.Acta neurochirurgica · 2023Article
- Review
- Review
- Mutational signature of extracranial meningioma metastases and their respective primary tumors.Acta neuropathologica communications · 2023Article
- Liquid biopsy evaluation of circulating tumor DNA, miRNAs, and cytokines in meningioma patients.Frontiers in neurology · 2023Article
- Specific gene expression signatures of low grade meningiomas.Frontiers in oncology · 2023Article
- Advances in Central Nervous System Tumor Classification.Advances in experimental medicine and biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been a recent revolution in our understanding of the genetic factors that drive meningioma, punctuating an equilibrium that has existed since Cushing's germinal studies nearly a century ago. A growing appreciation that meningiomas share similar biologic features with other malignancies has allowed extrapolation of management strategies and lessons from intra-axial central nervous system neoplasms and systemic cancers to meningiomas. These features include a natural proclivity for invasion, frequent intratumoral heterogeneity, and correlation between biologic profile and clinical behavior. Next-generation sequencing has characterized recurrent somatic mutations in NF2, TRAF7, KLF4, AKT1, SMO, and PIK3CA, which are collectively present in ~80% of sporadic meningiomas. Genomic features of meningioma further associate with tumor location, histologic subtype, and possibly clinical behavior. Such genomic decryption, along with advances in targeted pharmacotherapy, provides a maturing integrated view of meningiomas. We review recent advances in meningioma genomics and probe their potential applications in diagnostic, therapeutic, and prognostic frontiers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.